一般描述
因子 IX 是一种 55 kDa 的依赖维生素 K 的单链血浆酶原,在内源性和外源性凝血系统中起关键作用。
应用
因子 IX 是血浆凝血酶原,是凝血系统的关键。它已用于肝细胞癌(HCC)的门静脉血栓形成(PVT)的研究。研究表明,因子 IX 的异常会造成肝癌患者的 PVT。此外,它已用于研究炎症性肠病(IBD)患者凝血系统的变化。
外形
含 50%(v/v)甘油的水溶液
免责声明
仅供研究使用。本品在法国的科研应用受到监管,包括用于进口和出口活动(法国《公共卫生法典》Public Health Code Article L 1211-1 paragraph 2)。如《公共卫生法典》所述,购买者(即最终用户)需要从法国研究部(France Ministry of Research)获得进口授权。订购此产品即代表您已确认获得合法的进口授权。
储存分类代码
10 - Combustible liquids
WGK
WGK 1
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
Eyeshields, Gloves, type N95 (US)
法规信息
高风险级别生物产品--人源产品
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
Elena Santagostino
Thrombosis research, 131 Suppl 2, S7-10 (2013-03-30)
Hemophilia B is a severe bleeding disorder that is characterized by a deficiency or dysfunction of coagulation factor IX (FIX). Replacement therapy using recombinant or plasma-derived FIX is available, but the relatively short half-life of FIX (approximately 18 hours) necessitates
Priya Verghese et al.
Pediatric nephrology (Berlin, Germany), 28(5), 823-826 (2013-02-06)
Nephrotic syndrome (NS) is a recognized complication of immune tolerance induction (ITI) therapy, a treatment strategy used to treat inhibitors in patients with hemophilia B receiving factor IX concentrate. We present a 4-year-old boy with hemophilia B and an inhibitor
Uri Martinowitz et al.
Thrombosis research, 131 Suppl 2, S11-S14 (2013-03-30)
Recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) is a novel recombinant albumin fusion protein designed to extend the half-life of recombinant factor IX (rFIX), which is used in the management of hemophilia B. Clinical evaluation of rIX-FP
Cassandra L Pegg et al.
Glycoconjugate journal, 37(4), 471-483 (2020-05-08)
Human Factor IX is a highly post-translationally modified protein that is an important clotting factor in the blood coagulation cascade. Functional deficiencies in Factor IX result in the bleeding disorder haemophilia B, which is treated with plasma-derived or recombinant Factor
Mariko Yamamoto et al.
[Rinsho ketsueki] The Japanese journal of clinical hematology, 54(3), 300-304 (2013-05-17)
This report describes the successful management of neurosurgical procedures with continuous infusion of recombinant factor IX (rFIX). A 1-year-old boy with severe hemophilia B was administered prophylactic therapy with rFIX after intracranial bleeding. We found the enlargement of an arachnoid
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持